{"protocolSection":{"identificationModule":{"nctId":"NCT05035953","orgStudyIdInfo":{"id":"SMA-AIS-003"},"organization":{"fullName":"Huashan Hospital","class":"OTHER"},"briefTitle":"Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke","officialTitle":"Effect of Thrombolysis Combined With Edaravone Dexborneol for Acute Ischemic Stroke Patients: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial"},"statusModule":{"statusVerifiedDate":"2021-09","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-09-13","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2023-09-13","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-03-13","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-09-03","studyFirstSubmitQcDate":"2021-09-03","studyFirstPostDateStruct":{"date":"2021-09-05","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-09-03","lastUpdatePostDateStruct":{"date":"2021-09-05","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Qiang Dong","investigatorTitle":"MD, PhD, Director of Neurology Department","investigatorAffiliation":"Huashan Hospital"},"leadSponsor":{"name":"Huashan Hospital","class":"OTHER"},"collaborators":[{"name":"Shanghai Stroke Association","class":"UNKNOWN"}]},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"To explore the safety and efficacy of edaravone dexborneol for the treatment of acute ischemic stroke patients who received thrombolysis."},"conditionsModule":{"conditions":["Stroke, Ischemic"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":200,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Edaravone","type":"EXPERIMENTAL","description":"Edaravone Dexborneol injection","interventionNames":["Drug: Edaravone Dexborneol"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Edaravone Dexborneol matching injection","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Edaravone Dexborneol","description":"Edaravone Dexborneol 37.5 mg (containing Edaravone 30 mg and Dexborneol 7.5 mg), BID, 14 days, addition to thrombolysis","armGroupLabels":["Edaravone"]},{"type":"DRUG","name":"Placebo","description":"Edaravone Dexborneol matching injection, addition to thrombolysis","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The proportion of symptomatic intracranial hemorrhage","timeFrame":"36-48 hours"}],"secondaryOutcomes":[{"measure":"The proportion of symptomatic intracranial hemorrhage","timeFrame":"7 days"},{"measure":"The proportion of intracranial hemorrhage","timeFrame":"36-48 hours, 7 days"},{"measure":"The proportion of Participants With modified Rankin Scale (mRS) Score 0 to 1","timeFrame":"90 days"},{"measure":"The change in the NIH stroke scale (NIHSS) from the baseline","timeFrame":"36-48 hours, 7, 14 and 90 days"},{"measure":"The proportion of Participants With Barthel Index (BI) score greater than or equal to 95","timeFrame":"14 and 90 days"},{"measure":"Vascular recanalization","timeFrame":"36-48 hours"},{"measure":"Blood Brain Barrier Permeability","timeFrame":"36-48 hours"},{"measure":"Proportion of Encephaledema","timeFrame":"36-48 hours"},{"measure":"Proportion of Death","timeFrame":"90 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Acute ischemic stroke;\n* 18 to 80 years of age;\n* There are clear signs of neurological deficit: 8≤NIHSS score≤24;\n* Received alteplase thrombolysis therapy within 4.5 hours after onset;\n* Patients signed written inform consent\n\nExclusion Criteria:\n\n* Patients need endovascular therapy or bridge therapy;\n* Cranial CT scan finds intracranial bleeding disorders: hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage;\n* Severe head trauma or stroke, intracranial tumor or large intracranial aneurysm within 3 months;\n* Intracranial or intraspinal surgery within 3 months;\n* Active visceral hemorrhage\n* Major surgery within 2 weeks or arterial puncture within 1 week that is difficult to compress the hemostatic site;\n* Unknown onset time;\n* Rapid improvement of symptoms or mild symptoms before thrombolysis therapy;\n* A platelet count below 100,000/mm3 indicates a propensity for acute bleeding;\n* Therapeutic neuroprotective agents have been applied after onset of stroke, including commercially available edaravone, nimodipine, ganglioside, citicoline, piracetam, butyl benzene peptides, Urinary Kallidinogenase;\n* Patients with severe mental disorders and dementia;\n* ALT or AST is greater than 2.0×ULN or previously known liver diseases, such as acute hepatitis, chronic active hepatitis, liver cirrhosis;\n* Serum Creatinine (SCr) is greater than 1.5×ULN, Creatinine Clearance (CrCl) is less than 50 ml/min or previously known severe renal diseases;\n* Patients with malignant tumors or severe systemic disease;\n* allergic to edaravone , (+)-Borneol or related excipients;\n* Pregnant or lactating women;\n* Have major surgery within 4 weeks before enrollment;\n* Participated in other clinical studies within 30 days before randomization; or participating in other clinical trials at present;\n* The investigators consider the patients are not suitable for this trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Qiang Dong","role":"CONTACT","phone":"86-21-52887142","email":"qiang_dong163@163.com"}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077553","term":"Edaravone"}],"ancestors":[{"id":"D000016166","term":"Free Radical Scavengers"},{"id":"D000000975","term":"Antioxidants"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M1831","name":"Edaravone","asFound":"Lay","relevance":"HIGH"},{"id":"M3982","name":"Antioxidants","relevance":"LOW"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}